GLP-3 / Retatrutide: The Triple Agonist Explained

1. What 'GLP-3' actually means

The term 'GLP-3' is industry shorthand, not a formal pharmacological classification. Glucagon-like peptide-3 is not a recognised endogenous hormone in mammalian physiology. The label has come into common use as a generational descriptor: where 'GLP-1' refers to mono-agonists at the GLP-1 receptor and 'GLP-2' is sometimes informally applied to dual incretin agonists such as tirzepatide, 'GLP-3' describes the next step — single molecules that engage three metabolic-hormone receptors simultaneously.

Retatrutide is the most clinically advanced compound in this category at the time of writing. It is an investigational once-weekly subcutaneous peptide engineered by Eli Lilly to function as a balanced agonist at the GLP-1 receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. Several other triple agonists from Boehringer Ingelheim, Hanmi, and academic groups are in earlier development. (le Roux et al., 2024, Lancet Diabetes Endocrinol — PMID 38330987)

Because retatrutide is investigational, every claim about its efficacy or safety in this guide must be sourced to a specific publication or regulatory filing. The 'Pending Verification' section at the bottom of this page lists the searches required to anchor each quantitative statement to primary literature.

2. Molecular design and triple agonism

Retatrutide is a single linear peptide engineered with a fatty-acid side chain analogous to the strategy used in semaglutide and tirzepatide. The C20 fatty-diacid moiety promotes reversible binding to serum albumin, extends the circulating half-life to a range supportive of once-weekly dosing, and shields the peptide backbone from rapid proteolytic clearance. (see PubMed; primary medicinal-chemistry characterisation pending verification)

The molecule's most distinctive design feature is its receptor-selectivity profile. Native GLP-1 is selective for the GLP-1 receptor; native GIP is selective for the GIP receptor; native glucagon is selective for the glucagon receptor. Engineering a single sequence that engages all three receptors with intentionally chosen relative potencies is a non-trivial medicinal-chemistry achievement. The published pharmacology characterises retatrutide as a balanced agonist with somewhat stronger glucagon-receptor activity relative to its GLP-1R potency, although the precise potency ratios should be verified against the original publication. (see PubMed; receptor-potency data pending verification)

Why this combination? The therapeutic logic centres on combining the appetite-suppressive and insulinotropic effects of GLP-1R agonism with the additional insulinotropic and adipocyte-modulating effects of GIP-R agonism, plus the energy-expenditure-raising and hepatic-fat-reducing effects of glucagon-receptor agonism. The hypothesis is that a single agent engaging all three receptors can produce greater absolute weight loss than mono- or dual-receptor approaches without disproportionate increases in adverse events.

3. Mechanism — why three receptors

GLP-1 receptor contribution

The GLP-1R contribution mirrors the established mono-agonist class: glucose-dependent insulin secretion, glucagon suppression at high glucose levels, slowing of gastric emptying, and central appetite modulation through hindbrain and hypothalamic circuits.

GIP receptor contribution

GIP is the second incretin hormone. Its contribution to weight regulation has been historically debated, with both agonist and antagonist strategies showing weight-lowering signals in different preclinical and clinical settings. In the context of dual GLP-1/GIP agonism (tirzepatide), the GIP component is associated with additive insulinotropic activity and may attenuate certain GLP-1-mediated gastrointestinal side effects through central mechanisms. (see PubMed; review pending verification)

Glucagon receptor contribution

Glucagon is best known as a counter-regulatory hormone that raises hepatic glucose output. Sustained glucagon-receptor agonism, paradoxically, has been associated with reductions in hepatic lipid content, increases in resting energy expenditure, and improvements in liver enzymes in early-phase studies. The risk side of glucagon agonism — hyperglycaemia — is offset within retatrutide by the parallel GLP-1-driven insulinotropic activity. (see PubMed; verification pending)

The integrated effect, in published phase 2 data, is a greater magnitude of body-weight reduction than has been reported with mono- or dual-agonist programmes at comparable timepoints. Whether the integrated mechanism translates into proportionally greater cardiovascular, hepatic, or renal benefit will be answered only by the dedicated outcome trials that follow phase 3 efficacy.

4. Clinical programme to date

The publicly disclosed clinical programme for retatrutide includes phase 1 dose-escalation studies, phase 2 trials in obesity, type 2 diabetes, and metabolic-dysfunction-associated steatohepatitis, and a phase 3 obesity programme branded TRIUMPH.

Phase 2 obesity (Jastreboff et al.)

The phase 2 obesity study reported the most attention-grabbing weight-loss outcomes seen for any single-agent injectable to date. (Jastreboff et al., 2023, NEJM — PMID 37366315) Tolerability was characterised by GLP-1-class gastrointestinal events at incidences in line with related agents at comparable phase of titration.

Phase 2 type 2 diabetes (Rosenstock et al.)

The companion phase 2 study in adults with type 2 diabetes reported substantial reductions in HbA1c and body weight over 36 weeks. (Rosenstock et al., 2023, Lancet — PMID 37385280)

Metabolic-dysfunction-associated steatohepatitis (MASLD/MASH)

A dedicated phase 2 study evaluated reductions in hepatic fat fraction (assessed by MRI-PDFF) in adults with MASLD. (Sanyal et al., 2024, Nat Med — PMID 38858523)

Phase 3 (TRIUMPH programme)

The TRIUMPH programme is the phase 3 obesity development plan; TRIUMPH-DM addresses type 2 diabetes. Specific NCT registration numbers, primary endpoints, and projected readouts should be verified against the current ClinicalTrials.gov entries. (see ClinicalTrials.gov for TRIUMPH programme entries)

5. How it compares to GLP-1 and dual agonists

Direct head-to-head trial data between retatrutide and approved GLP-1 RAs or tirzepatide are limited at the time of writing. Cross-trial comparisons are inherently confounded by differences in patient populations, titration schedules, and study durations. With those caveats, indicative observations from the published phase 2 data include:

• The magnitude of placebo-adjusted body-weight reduction reported at the highest tested dose in phase 2 retatrutide exceeded the corresponding magnitudes in pivotal trials of semaglutide 2.4 mg and tirzepatide at the equivalent timepoint, although the populations and durations differ. (cross-trial comparison; see STEP 1, SURMOUNT-1, and retatrutide phase 2 primary publications)
• Tolerability profile is qualitatively similar to other long-acting incretin-based therapies — predominantly gastrointestinal — with rates that should be expected to vary by titration schedule and dose.
• Effects on lipid metabolism and hepatic fat content are more pronounced with retatrutide than with mono-agonist GLP-1 therapy in the published comparisons, consistent with the glucagon-receptor contribution.

For a structured side-by-side that updates as new trials publish, see the dedicated comparison page retatrutide vs semaglutide vs tirzepatide and the broader pillar guide How Weight-Loss Peptides Compare.

6. Open questions and unknowns

• Long-term cardiovascular outcomes. No completed dedicated outcome trial has yet been reported. Whether triple agonism delivers additive cardiovascular benefit beyond GLP-1 or GLP-1/GIP combinations is undetermined.
• Lean-mass preservation. Magnitude of total weight loss raises perennial concern about the lean-to-fat composition of that loss. Direct DXA or MRI body-composition data from phase 3 are awaited. (see PubMed; phase 3 sub-study data pending)
• Discontinuation and weight regain. As with any chronic incretin therapy, the durability of weight loss after discontinuation is unresolved. Randomised-withdrawal designs, analogous to STEP 4 for semaglutide, will be needed.
• Glucagon-receptor safety signals. Long-term effects of sustained glucagon-receptor agonism on glycaemia in vulnerable subgroups, on amino-acid metabolism, and on rare hepatic events require monitoring through phase 3 and post-marketing data.
• Drug interactions and special populations. Pharmacokinetic data in renal impairment, hepatic impairment, pregnancy, and paediatric populations are incomplete. Most early labelling, when granted, will reflect the populations enrolled in pivotal trials.

7. Regulatory status and access

Retatrutide is an investigational compound. At the time of writing it has not received marketing authorisation from the U.S. Food and Drug Administration, the European Medicines Agency, or other major regulators. (see FDA.gov; current designation pending verification) Prescription access through compounding pharmacies for retatrutide as a weight-loss therapy is not currently consistent with FDA guidance on bulk-substance compounding for non-approved active ingredients, and clinicians and patients should seek current authoritative guidance before considering any non-trial route.

Research-grade retatrutide is supplied to qualified institutional researchers strictly for in vitro and laboratory investigation. Any product distributed in this channel — including compounds listed at /products/glp3r-10mg-30mg/ — is labelled For Research Use Only and is not intended for human or veterinary use. The black-market supply of retatrutide for self-administration carries unverifiable purity and identity, and is addressed in the dedicated black-market warning page.

References

This guide cites primary peer-reviewed and regulatory sources where the underlying claim has been verified. A small number of supporting items remain in active verification and are listed below for transparency.

Verified primary references

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2. NEJM 2023. PMID 37366315.
2. Rosenstock J et al. Retatrutide Phase 2 in Type 2 Diabetes. Lancet 2023. PMID 37385280.
3. Sanyal AJ et al. Triple Hormone Receptor Agonist Retatrutide for MASLD — Phase 2a. Nat Med 2024. PMID 38858523.
4. le Roux CW et al. Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity — Phase 2. Lancet Diabetes Endocrinol 2024. PMID 38330987.

Still seeking primary citation

• Retatrutide medicinal-chemistry / structural-PK characterisation (primary publication; verification pending)
• Retatrutide receptor-potency ratios at GLP-1R, GIP-R, GCGR (primary publication; verification pending)
• GIP receptor agonism and weight regulation — review
• Glucagon receptor agonism and energy expenditure — primary clinical-pharmacology data
• TRIUMPH and TRIUMPH-DM ClinicalTrials.gov NCT identifiers
• Retatrutide phase 3 body-composition (lean vs fat mass) sub-study — pending readout
• Retatrutide FDA Fast Track / Breakthrough Therapy designation status